Stablepharma

Executive Summary

Stablepharma is a UK-based biotechnology company developing thermostable vaccines that eliminate the need for cold chain storage and distribution. Founded in 2013, the company addresses a critical global health challenge: over 50% of vaccines are wasted due to temperature sensitivity. By stabilizing vaccines at room temperature, Stablepharma's platform aims to dramatically reduce wastage, improve access in low-resource settings, and lower distribution costs. The company is currently in Phase 1 clinical development for its lead vaccine candidate. With a focus on global health equity, Stablepharma's technology has the potential to transform vaccine logistics worldwide. Given its early stage, the company faces significant clinical, regulatory, and commercial risks, but the market need and potential impact are substantial.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Clinical Data Readout60% success
• Q4 2026Partnership with Global Health Organization (e.g., WHO, Gavi)30% success
• Q2 2027Series B Funding or Grant Award50% success